×




Pfizer's Centers for Therapeutic Innovation (CTI) Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Pfizer's Centers for Therapeutic Innovation (CTI) case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Pfizer's Centers for Therapeutic Innovation (CTI) case study is a Harvard Business School (HBR) case study written by Gary P. Pisano, James Weber, Kaitlyn Szydlowski. The Pfizer's Centers for Therapeutic Innovation (CTI) (referred as “Pfizer Academic” from here on) case study provides evaluation & decision scenario in field of Technology & Operations. It also touches upon business topics such as - Value proposition, Operations management, Research & development, Strategy, Technology.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Pfizer's Centers for Therapeutic Innovation (CTI) Case Study


In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration with Pfizer and academic medical researchers with the purpose of developing new, innovative drugs candidates for testing in patients. Project teams consisted of Pfizer scientists and academics working side-by-side to reduce the time needed to bring a therapeutic drug from the lab to a patient's bedside. This case explores the academic collaboration model developed by Pfizer. What were the strengths of and challenges facing this model? How would the model evolve in the future? And how would new, similar collaboration models surfacing at other major pharmaceutical companies pose a threat to the Pfizer model?


Case Authors : Gary P. Pisano, James Weber, Kaitlyn Szydlowski

Topic : Technology & Operations

Related Areas : Operations management, Research & development, Strategy, Technology




Calculating Net Present Value (NPV) at 6% for Pfizer's Centers for Therapeutic Innovation (CTI) Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10020707) -10020707 - -
Year 1 3470698 -6550009 3470698 0.9434 3274243
Year 2 3981292 -2568717 7451990 0.89 3543336
Year 3 3950274 1381557 11402264 0.8396 3316726
Year 4 3234413 4615970 14636677 0.7921 2561958
TOTAL 14636677 12696263




The Net Present Value at 6% discount rate is 2675556

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Internal Rate of Return
3. Net Present Value
4. Profitability Index

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Pfizer Academic shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Pfizer Academic have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.






Formula and Steps to Calculate Net Present Value (NPV) of Pfizer's Centers for Therapeutic Innovation (CTI)

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Technology & Operations Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Pfizer Academic often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Pfizer Academic needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10020707) -10020707 - -
Year 1 3470698 -6550009 3470698 0.8696 3017998
Year 2 3981292 -2568717 7451990 0.7561 3010429
Year 3 3950274 1381557 11402264 0.6575 2597369
Year 4 3234413 4615970 14636677 0.5718 1849286
TOTAL 10475082


The Net NPV after 4 years is 454375

(10475082 - 10020707 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10020707) -10020707 - -
Year 1 3470698 -6550009 3470698 0.8333 2892248
Year 2 3981292 -2568717 7451990 0.6944 2764786
Year 3 3950274 1381557 11402264 0.5787 2286038
Year 4 3234413 4615970 14636677 0.4823 1559806
TOTAL 9502878


The Net NPV after 4 years is -517829

At 20% discount rate the NPV is negative (9502878 - 10020707 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Pfizer Academic to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Pfizer Academic has a NPV value higher than Zero then finance managers at Pfizer Academic can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Pfizer Academic, then the stock price of the Pfizer Academic should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Pfizer Academic should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

What will be a multi year spillover effect of various taxation regulations.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Pfizer's Centers for Therapeutic Innovation (CTI)

References & Further Readings

Gary P. Pisano, James Weber, Kaitlyn Szydlowski (2018), "Pfizer's Centers for Therapeutic Innovation (CTI) Harvard Business Review Case Study. Published by HBR Publications.


MULTIPLAN ON SWOT Analysis / TOWS Matrix

Services , Real Estate Operations


Client Service SWOT Analysis / TOWS Matrix

Technology , Software & Programming


Fusion Interactive Corp SWOT Analysis / TOWS Matrix

Consumer/Non-Cyclical , Food Processing


Mission Newenergy Ltd SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


Ioneer SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


DMG Mori Seiki SWOT Analysis / TOWS Matrix

Capital Goods , Misc. Capital Goods


SIG SWOT Analysis / TOWS Matrix

Technology , Computer Services


Turbo Mech Bhd SWOT Analysis / TOWS Matrix

Capital Goods , Misc. Capital Goods


Nihon Denkei SWOT Analysis / TOWS Matrix

Capital Goods , Misc. Capital Goods